Key statistics dashboard for Janux Therapeutics, Inc. (JANX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors.
Stock Data
| Price | $16.25 |
| Market Cap | $991M |
| Enterprise Value | $995.8M |
| Beta | 2.81 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -9.91 |
| Price / Book | 1.10 |
| P/S | 31.08 |
| EV/EBITDA | -9.85 |
| EV/Sales | 31.24 |
| EV/FCF | -18.26 |
| P/FCF | -18.17 |
| Earnings Yield | -9.92% |
| FCF Yield | -5.44% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 68.91% |
| EBIT Margin | -321.81% |
| EBITDA Margin | -317.14% |
| Operating Margin | -450.30% |
| Net Margin | -321.81% |
| Return on Equity | -10.79% |
| Return on Assets | -10.18% |
| Return on Invested Capital | -15.11% |
| Return on Capital Employed | -15.15% |
Financial Health
| Current Ratio | 16.35 |
| Quick Ratio | 16.35 |
| Cash Ratio | 0.46 |
| Debt / Equity | 0.02 |
| Debt / Assets | 2.08% |
| Net Debt / EBITDA | 0.07 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.51 |
| Book Value per share | 14.74 |
| Cash per share | 15.43 |
| FCF per share | -0.87 |
| Tangible Book Value per share | 14.74 |
| Dividend per share | 0.00 |
Related companies: ABCL · BHVN · CLDX · HRMY · IMNM · MAZE · NUVB
Explore sector: Healthcare · Biotechnology
More sections of JANX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks